ProMIS Neurosciences Inc

ProMIS Neurosciences insider buys reveal executive confidence amid breakthrough therapy milestones, potential upside from warrants and upcoming Phase‑III data.

ABG Management’s $12.13 stake in ProMIS Neurosciences, paired with milestone‑triggered warrants, bets on PMN310’s upcoming 2026 data—could spark a rapid share surge if tau‑protein therapy hits key clinical goals.